HomeAuthor Christina

Stuart Therapeutics Announces Corneal Epithelial Healing and Organization Pre-Clinical Results for its Potential Dry Eye Therapeutic

Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced important pre-clinical in vivo proof of concept results for its collagen mimetic polypeptide therapeutic, PolyColTM (PolyCol). The company announced additional important results from its mouse eye wound tests. Previous results showed statistically significant results for both acceleration of epithelial cell growth and...

Stuart Therapeutics Announces Important Pre-Clinical Results for ST-100

Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced important pre-clinical in vivo proof of concept results for its collagen mimetic polypeptide therapeutic, PolyColTM (PolyCol). Mouse eye wound tests conducted at the University of Louisville demonstrated rapid, high quality healing of corneal wounds, results that support Stuart’s development of PolyCol as...

Stuart Therapeutics has been selected as a semi-finalist in the BioPitch competition at the 21st annual BioFlorida Conference

Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced today that it has been selected as a semi-finalist in the BioPitch competition at the 21st annual BioFlorida Conference, October 14th – 16th in Ft. Lauderdale, Florida. The BioPitch competition annually selects 15 companies as semi-finalists that present in front of angel...

Stuart Therapeutics Selected to Present at the Next Generation Session at BioEurope in November

Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced today that it has been selected to present as one of a handful of emerging companies at the Next Generation Session during the 24th annual BIO-Europe Conference, November 5 -7, 2018, in Copenhagen, Denmark. BIO-Europe is the largest life science partnering conference...

Stuart Therapeutics Joins The Jupiter Life Science Initiative

Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced today that it has joined the Jupiter Life Science Initiative (JLSI) in Jupiter, Florida. Stuart will establish its research and development laboratory facility there, where the company will conduct a series of pre-clinical development efforts to advance its two platform technologies, PolyColTM...

ST-101 Announcement

Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced today that it has completed the acquisition of the intellectual property rights to a patented bioresorbable drug delivery insert that is designed for both anterior and posterior segment ophthalmic diseases. The technology, designated ST-101 by Stuart, is being evaluated for its ability...

Stuart Therapeutics Adds Internationally Recognized Cornea and Ophthalmic Surgery Experts to its Scientific Advisory Board

Stuart Therapeutics (ST), a pre-clinical stage company developing advanced ophthalmic therapeutics, today announced key additions to its Scientific Advisory Board. The new additions bring some of the United States’ premier experts in anterior segment ophthalmology into the ST organization. “We are proud that some of the foremost leaders in ophthalmology in the United States have...

Ronald T. Raines, PhD, Joins the Stuart Therapeutics Scientific Advisory Board

Stuart Therapeutics, a pre-clinical stage company developing advanced ophthalmic therapeutics, today announced that Ronald T. Raines, PhD, the Firmenich Professor of Chemistry at the Massachusetts Institute of Technology (MIT), has joined the company’s Scientific Advisory Board. Ronald T. Raines, Ph.D., is an Associate Member of the Broad Institute of MIT and Harvard, and an Affiliate...